CAR-Msolid tumors
…Background Chimeric antigen receptor macrophages (CAR-M) represent a promising immunotherapy candidate for solid tumors…
10,506articles mentioning drugs
58,393drug mentions
9,496distinct drugs extracted
0%of mentions human-reviewed
All extracted drugs
Showing 721–780 of 9,496, ordered by supporting articles. Choose a drug to see its evidence.
Dapsone5Diclofenac5Epirubicin5FibroScan5Hyperbaric bupivacaine5ICB5ICS/LABA5IFNγ5IL-185SARS-CoV-25donanemab5immunomodulators5low-dose aspirin5tapentadol5thiazolidinediones56-mercaptopurine5High-dose steroids5JAK inhibitors5Letrozole5Mercaptopurine5Steroid5Trastuzumab Emtansine5Vitamin B125antiseizure medication5candesartan5ganciclovir5immune checkpoint inhibitor5non-steroidal anti-inflammatory drug5normal saline5nortriptyline5supplemental oxygen5ASMs5Atracurium5Bacillus Calmette-Guérin5Bendamustine5High-dose intravenous methylprednisolone5SF-365Selective Serotonin Reuptake Inhibitors5acetic acid5contraceptives5delpar5intravenous ceftriaxone5liposomal amphotericin B5prescription opioids5topical corticosteroids5venlafaxine5DPP4i4ELA4Estrogen4Rilvegostomig4HM163904Alectinib4Penumbra4RP14LEvoSimendan4Nipocalimab4Dinutuximab4SEL4BLM4IL-17i4
Articles mentioning drugs
10,506 articles · page 567 of 876CD73CD73 CARMultiple myelomamyelomasolid tumorseLife
…n of CD73 on U266B1 cells at high levels (>90%). Treatment with CD73 mAb had a significant cytotoxic effect against U266B1 cells in …
LipidBrick® Cell Ready
…eptor (CAR) T cell manufacturing is associated with high costs. LipidBrick® Cell Ready is a novel lipid-based nanoparticle solution that can be easily…
anti-CD33 TMacute myeloid leukemia
… UniCAR-T cells redirected with increasing concentrations of an anti-CD33 TM against acute myeloid leukemia (HL-60) cells.Results Tracking t…
4-1BBMayo Clinic Division of HematologyMayo Clinic Center for Individualized MedicineMayo Clinicchimeric antigen receptor T (CART) cell therapy
…hese two genes in CART cells that were costimulated with either 4-1BB or CD28. Ultimately, our study indicates that UACA and NEFM ove…
76.5%
CART87urokinase plasminogen activator (uPA)Colorectal cancerCRCCAR-T cell therapysolid tumorsHEK293CAR-T therapyHuman Protein AtlasLS174T
… future preclinical in vivo studies and clinical development of CART87.…
CAR-TCAR-NKTransCure bioServicesinfectious or inflammatory diseasesFrench Ministry of Higher Education and ResearchAAALAC-accredited
…ful applications of this approach across diverse CGTs—including CAR-T, CAR-NK, TCR-T cells, and extracellular vesicles—in both autolo…
CAR-MoPMAbreast cancersolid tumorsBWH Innovation FundThe Harvard Ludwig CenterBCcellular therapies
…B sensitivity in vivo. These results suggest that TAM-targeting CAR-Mo offers a first-in-class platform to improve the effectiveness o…
dnTGFβRIISTEAP2Metastatic castration-resistant prostate cancer (mCRPC)mCRPCchimeric antigen receptor (CAR) T cell therapy
…d (4) overcoming immunosuppression by armoring CAR T cells with dnTGFβRII. Bispecific secretion is restricted to NFAT-activated CAR T cel…
RNF166solid tumorshematologic cancersmetastatic melanomaACT
…in part by changes in E3 expression. Notably, overexpression of RNF166 in T-cells significantly enhances persistence, highlighting a p…
IL-15-armored CARIL-15hepatocellular carcinomasolid tumorsNational Natural Science Foundation of China GrantsHCCNanfang HospitalCAR-NK therapyhematologic malignanciesGRGZ2022330+2 more
…nclusions Our results demonstrate that non-viral integration of IL-15-armored CAR into the CISH locus via a simplified one-step genome editing pr…
IL-12
…1-00842-6Yang Z, et al. Nanoscale, antigen encounter-dependent, IL-12 delivery by CAR T cells plus PD-L1 blockade for cancer treatmen…